Merck & Co., Inc. Stock

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX 11:18:47 2024-04-23 am EDT 5-day change 1st Jan Change
127.3 USD +0.31% Intraday chart for Merck & Co., Inc. +1.94% +16.94%
Sales 2024 * 63.82B Sales 2025 * 68.17B Capitalization 322B
Net income 2024 * 19.48B Net income 2025 * 21.78B EV / Sales 2024 * 5.35 x
Net Debt 2024 * 19.65B Net Debt 2025 * 7.53B EV / Sales 2025 * 4.83 x
P/E ratio 2024 *
16.4 x
P/E ratio 2025 *
14.3 x
Employees 71,000
Yield 2024 *
2.42%
Yield 2025 *
2.55%
Free-Float 70.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.92%
1 week+0.59%
Current month-3.80%
1 month+2.49%
3 months+6.29%
6 months+23.64%
Current year+16.44%
More quotes
1 week
124.50
Extreme 124.5
128.08
1 month
123.77
Extreme 123.77
133.10
Current year
109.16
Extreme 109.16
133.10
1 year
99.14
Extreme 99.14
133.10
3 years
70.89
Extreme 70.89
133.10
5 years
65.25
Extreme 65.25
133.10
10 years
45.69
Extreme 45.69
133.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-04-23 127.5 +0.44% 1 888 363
24-04-22 126.9 +0.92% 7,805,992
24-04-19 125.8 +0.44% 8,404,345
24-04-18 125.2 -0.11% 5,992,700
24-04-17 125.4 +0.25% 6,122,908

Delayed Quote Nyse, April 22, 2024 at 04:00 pm EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
126.9 USD
Average target price
137.6 USD
Spread / Average Target
+8.38%
Consensus